February 26, 2020 / 1:42 PM / a month ago

BRIEF-Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Feb 26 (Reuters) - Cytokinetics Inc:

* AMGEN, CYTOKINETICS AND SERVIER ANNOUNCE CONTINUATION OF GALACTIC-HF FOLLOWING PLANNED INTERIM ANALYSIS

* CYTOKINETICS-DATA MONITORING COMMITTEE RECOMMENDS PHASE 3 CLINICAL TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH HEART FAILURE CONTINUE WITHOUT CHANGES

* CYTOKINETICS INC - TOPLINE RESULTS EXPECTED IN Q4 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below